National Institutes of Health's National Laboratory for Cancer Research: RAS Drug Discovery at Frederick National Laboratory Reaches Lung Cancer Patients in a Clinical Trial
October 09, 2024
October 09, 2024
FREDERICK, Maryland, Oct. 9 (TNSres) -- The National Institutes of Health's National Laboratory for Cancer Research issued the following news:
By Mary Ellen Hackett
An investigational treatment co-discovered by RAS Initiative scientists at the Frederick National Laboratory (FNL) is now being tested in patients with advanced non-small cell lung cancer driven by mutant KRAS G12C.
BBO-8520 is being evaluated in a Phase1a/1b clinical trial, the ONKORAS-101 Stu . . .
By Mary Ellen Hackett
An investigational treatment co-discovered by RAS Initiative scientists at the Frederick National Laboratory (FNL) is now being tested in patients with advanced non-small cell lung cancer driven by mutant KRAS G12C.
BBO-8520 is being evaluated in a Phase1a/1b clinical trial, the ONKORAS-101 Stu . . .